- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia ; volume:15 ; number:6 ; day:12 ; month:6 ; year:2024 ; pages:1-11 ; date:6.2024
Cell death & disease ; 15, Heft 6 (12.6.2024), 1-11, 6.2024
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-024-06810-7
- URN
-
urn:nbn:de:101:1-2408182107509.844071804530
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nwosu, Gus O.
- Ross, David M.
- Powell, Jason A.
- Pitson, Stuart M.
- SpringerLink (Online service)
Other Objects (12)
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia